Evogene Ltd. revenue

Evogene Ltd.'s revenue was $3.9m in fiscal 2025, down 30.9% on the year before. Since fiscal 2015 ($11.1m) it has grown at a compound -10.1% a year.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Evogene Ltd.: revenue history, annual
Fiscal year	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	11	7	3	2	1	1	1	2	3	6	4
Growth on the year before	—	−41.2%	−48.3%	−48.3%	−56.9%	+38.1%	−10.6%	+80.1%	+78.0%	+87.0%	−30.9%
Gross profit	3	1	1	0	0	0	0	1	1	3	−0
Gross margin	25.8%	13.8%	15.9%	16.9%	55.6%	44.8%	17.5%	45.7%	50.0%	57.3%	−6.3%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Evogene Ltd.	$3.9m	-30.9%	—
DBV Technologies S.a.	$3.8m	-31.6%	-11.6%
Dyadic International Inc	$3.8m	-8.0%	3.4%
Aligos Therapeutics, Inc.	$3.7m	19.4%	-5.5%
Camp4 Therapeutics Corp	$4.2m	40.2%	—
Curis Inc	$4.3m	-62.2%	-25.0%

Compare with peers

Head to head: DBVT vs EVGN DYAI vs EVGN ALGS vs EVGN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Evogene Ltd.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Evogene Ltd.